Format

Send to

Choose Destination
Sci Rep. 2017 Feb 8;7:42108. doi: 10.1038/srep42108.

N,N Dimethylacetamide a drug excipient that acts as bromodomain ligand for osteoporosis treatment.

Author information

1
Oral Biotechnology &Bioengineering, Center for Dental Medicine/MKG, University of Zürich, Switzerland.
2
Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland.
3
Department of Biochemistry, University of Zurich, Switzerland.
4
CABMM, Center for Applied Biotechnology and Molecular Medicine, University of Zurich, Zurich, Switzerland.

Abstract

N,N-Dimethylacetamide (DMA) is a water-miscible solvent, FDA approved as excipient and therefore widely used as drug-delivery vehicle. As such, DMA should be devoid of any bioactivity. Here we report that DMA is epigenetically active since it binds bromodomains and inhibits osteoclastogenesis and inflammation. Moreover, DMA enhances bone regeneration in vivo. Therefore, our in vivo and in vitro data reveal DMA's potential as an anti-osteoporotic agent via the inhibition of osteoclast mediated bone resorption and enhanced bone regeneration. Our results highlight the potential therapeutic benefits of DMA and the need for reconsideration of previous reports where DMA was used as an 'inactive' drug-delivery vehicle.

PMID:
28176838
PMCID:
PMC5296751
DOI:
10.1038/srep42108
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center